BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.94
-0.08 (-0.89%)
At close: Jul 3, 2025, 1:00 PM
8.94
0.00 (0.00%)
After-hours: Jul 3, 2025, 4:38 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts that cover BioCryst Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $16.7, which forecasts a 86.8% increase in the stock price over the next year. The lowest target is $11 and the highest is $30.
Price Target: $16.7 (+86.8%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 3 | 3 | 4 | 5 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +67.79% | Jul 1, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $13 | Buy | Reiterates | $13 | +45.41% | Jun 30, 2025 |
| Wedbush | Wedbush | Buy Maintains $16 → $18 | Buy | Maintains | $16 → $18 | +101.34% | Jun 30, 2025 |
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +90.16% | Jun 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +90.16% | Jun 25, 2025 |
Financial Forecast
Revenue This Year
626.68M
from 450.71M
Increased by 39.04%
Revenue Next Year
709.80M
from 626.68M
Increased by 13.26%
EPS This Year
0.12
from -0.43
EPS Next Year
0.36
from 0.12
Increased by 189.82%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 661.4M | 775.7M | 895.7M | ||
| Avg | 626.7M | 709.8M | 794.8M | ||
| Low | 588.1M | 643.2M | 693.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 46.7% | 23.8% | 26.2% | ||
| Avg | 39.0% | 13.3% | 12.0% | ||
| Low | 30.5% | 2.6% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.37 | 0.82 | 1.22 | ||
| Avg | 0.12 | 0.36 | 0.63 | ||
| Low | - | 0.04 | 0.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 563.0% | 239.5% | ||
| Avg | - | 189.8% | 76.7% | ||
| Low | - | -68.3% | -23.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.